(UroToday.com) Outcomes of immunotherapy have been the highlight of meetings over the last decade. At the 2020 European Association of Urology (EAU) Virtual Meeting, Dr. Yohann Loriot discussed novel treatment options beyond immunotherapy. As noted by Dr. Loriot, the vast majority of trials with new drugs are investigating immunotherapy, but a better understanding of the tumor biology is identifying new targets. Currently, fibroblast growth factor receptors (FGFR) inhibitors and antibody-drug conjugates are the best approaches, and as such precision-medicine should be implemented. In muscle invasive bladder cancer, several genetic alterations are potentially targetable, including FGFR3, HHRm, HER2, components of angiogenesis, and the epigenome.